Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Recombinant Factor VIIa Clear all
Completed No phase listed Observational

The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry

NCT00328133
View directory record Official record
Conditions
Traumatic Hemorrhage, Hemorrhagic Shock
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

NCT03196284
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
Concizumab, Eptacog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

NCT00951405
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII, long acting
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

NCT04548791
View directory record Official record
Conditions
Factor VII Deficiency, Glanzmann Thrombasthenia, Hemophilia A With Inhibitor
Interventions
Coagulation Factor VIIa variant
Biological
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
7
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 4 Interventional

Trial of NovoSeven® in Haemophilia - Joint Bleeds

NCT00108797
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
eptacog alfa (activated), Feiba VH
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 20 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
20
States / cities
Little Rock, Arkansas • Berkeley, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 1 Interventional

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

NCT01561950
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
eptacog alfa (activated), clopidogrel, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting No phase listed Observational

Treatment of Hemophilia A Patients With FVIII Inhibitors

NCT04023019
View directory record Official record
Conditions
Hemophilia A
Interventions
Nuwiq, Octanate, Wilate, Emicizumab, Recombinant factor VIIa (rFVIIa), Activated prothrombin complex concentrate (aPCC)
Biological
Lead sponsor
Emory University
Other
Eligibility
Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 3 Interventional

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

NCT04489537
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions
MarzAA
Biological
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds

NCT00486278
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A, Haemophilia B
Interventions
eptacog alfa (activated), vatreptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn

NCT00243243
View directory record Official record
Conditions
Burns
Interventions
Recombinant Factor VIIa, Placebo
Drug
Lead sponsor
United States Army Institute of Surgical Research
Federal
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting Phase 3 Interventional

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

NCT07227246
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Recombinant Factor VIIa, Biological/Vaccine: Placebo
Biological
Lead sponsor
Joseph Broderick, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
49
States / cities
Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B

NCT01708564
View directory record Official record
Conditions
Hemophilia
Interventions
rhFVIIa
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Sacramento, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa

NCT02448680
View directory record Official record
Conditions
Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Interventions
Coagulation FVIIa (Recombinant)
Biological
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Oklahoma City, Oklahoma • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional

Use of Activated Recombinant Human Factor VII in Cardiac Surgery

NCT00154427
View directory record Official record
Conditions
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 24, 2026, 5:34 AM EDT
Active, not recruiting Phase 3 Interventional

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

NCT03496883
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Recombinant Activated Factor VII (rFVIIa), Placebo
Biological
Lead sponsor
Joseph Broderick, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Baldwin Park, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

NCT02622321
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, rFVIIa, aPCC
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

NCT00127283
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
77
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Response to Recombinant Factor VIIa When Administered for Bleed

NCT00104455
View directory record Official record
Conditions
Congenital Bleeding Disorder, Healthy
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 24, 2026, 5:34 AM EDT
Completed No phase listed Observational Results available

PROPACT: Retrospective Prophylaxis Patient Case Collection

NCT00882778
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting Phase 2 Interventional

Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)

NCT07136857
View directory record Official record
Conditions
Glanzmann Thrombasthenia
Interventions
EPTACOG BETA
Drug
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

NCT00108758
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
Berkeley, California • Los Angeles, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 24, 2026, 5:34 AM EDT
Completed No phase listed Observational

Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX

NCT00710619
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII, Feiba VH
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 1 Interventional Results available

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

NCT01439971
View directory record Official record
Conditions
Hemophilia A
Interventions
PF-05280602
Biological
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Early Phase 1 Interventional

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

NCT05281718
View directory record Official record
Conditions
Hemophilia A
Interventions
Factor IX
Drug
Lead sponsor
Tulane University
Other
Eligibility
12 Years to 120 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Metairie, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 24, 2026, 5:34 AM EDT